theMednet - Since the approval of Carbo/VP-16/Atezolizumab (IMpower133) for extensive stage small cell lung cancer, how are you treating those patients who progress > 6 months after chemotherapy alone who were treated prior to the approval of IMpower133?

Topics: Thoracic Malignancies • Medical Oncology

Since the approval of Carbo/VP-16/Atezolizumab (IMpower133) for extensive stage small cell lung cancer, how are you treating those patients who progress > 6 months after chemotherapy alone who were treated prior to the approval of IMpower133?

Would you treat with platinum-etoposide alone again, or would you add atezolizumab?

IMpower133

Answer from: Medical Oncologist at Community Practice

2nd line anti-PD1 (+/- anti-CTLA4) is reasonable for patients who did not receive atezo in the 1st line setting.

Comments

Medical Oncologist at Wenatchee Valley Med Center
Is there any reason to think that if they did rece...

Related Questions